Activist Oramed Sells Direct Stake, Shifts to Options Strategy After Proxy Settlement

summarizeSummary

Oramed Pharmaceuticals, a former activist investor, sold its direct equity stake in Nano Dimension, reducing its beneficial ownership below 5%, but simultaneously established a new options position.

check_boxKey Events · Ownership and Investor Activity · NNDM

• Significant Share Sale

  Oramed Pharmaceuticals sold 8,200,000 ordinary shares at $1.55 per share, totaling $12.71 million.

• Reduced Ownership Below 5%

  Following the sale, Oramed Pharmaceuticals ceased to beneficially own more than five percent of Nano Dimension's outstanding shares.

• Shift to Options Strategy

  Concurrently, Oramed purchased call options and sold put options referencing 8,200,000 shares, indicating a shift from direct equity ownership to a derivative-based exposure.

• Follows Proxy Settlement

  These transactions occurred on July 20, 2026, just before the announcement of the settlement of the proxy contest between Nano Dimension and Murchinson Ltd. on July 21, 2026.

auto_awesomeAnalysis · NNDM · Manufacturing

Oramed Pharmaceuticals, a former activist shareholder, has sold its direct equity stake in Nano Dimension, reducing its beneficial ownership below 5%. This move follows the recent settlement of the proxy contest with Murchinson Ltd. and Oramed's prior opposition to a major acquisition. While Oramed sold its shares, it simultaneously entered into a complex options strategy, purchasing call options and selling put options, indicating a continued, albeit indirect, bullish exposure to the stock. This strategic shift by a significant investor marks a change in their direct involvement following a period of intense corporate governance activity.